Xenon Pharmaceuticals stock trades at EUR 32.70 after FDA filing
Published on 09/30/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Xenon Pharmaceuticals (ISIN CA98420N1050) was trading at EUR 32.70 at Lang & Schwarz on September 30, 2026, at 4:13 p.m. CEST, down 0.61 percent from the prior close of EUR 32.90. The company filed a U.S. FDA application for azetukalner in focal seizures on September 17, 2026, while its psychiatry program faced a safety-related enrollment pause.
FDA filing meets psychiatry setback
According to Xenon Pharmaceuticals on September 17, 2026, the azetukalner New Drug Application is based on two randomized trials in focal seizures. The same release said the company voluntarily paused new enrollment in major depressive disorder and bipolar depression studies while current participants remained active.
Reuters reported on September 17, 2026, that the observed events included confusion, speech difficulties and motor coordination issues. Xenon said it was evaluating dose adjustments, while the epilepsy program was unaffected.
Epilepsy program still advances
The September 17, 2026 release said Xenon's epilepsy program had generated more than 1,500 patient-years of safety and exposure data. Phase 3 X-TOLE3 and X-ACKT studies continued enrolling patients, giving the FDA filing a separate development path from the psychiatry setback.
The company also said X-NOVA2 enrollment had reached 80 percent of its initial target and that topline data were expected in Q1 2027, according to Xenon Pharmaceuticals.
Analyst targets stay above the quote
For the quarter ended June 30, 2026, Xenon reported EPS of USD -1.11 versus a USD -1.16 consensus estimate, according to MarketBeat on September 21, 2026. The comparison shows a USD 0.05 smaller loss than expected, although the company remains loss-making as it funds late-stage development.
Investing.com listed an average 12-month analyst target of USD 74.31 from 18 analysts on September 29, 2026. The same page showed a USD 36.07 to USD 72.66 52-week range, placing the current Nasdaq quote near the lower boundary of that interval.
Xenon Pharmaceuticals stock trades at EUR 32.70
Xenon Pharmaceuticals stock was trading at EUR 32.70 at Lang & Schwarz on September 30, 2026, at 4:13 p.m. CEST. The quote was down 0.61 percent versus the Lang & Schwarz prior close of EUR 32.90 on September 29, 2026.
Xenon Pharmaceuticals stock data
- Company: Xenon Pharmaceuticals Inc.
- ISIN: CA98420N1050
- Ticker: XENE
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of September 30, 2026, 4:13 p.m. CEST): EUR 32.70
- Change versus prior close: minus 0.61 percent
- Prior close Lang & Schwarz (September 29, 2026): EUR 32.90
- Market capitalization: USD 3.6 billion (as of September 30, 2026)
- 52-week range: USD 36.07-72.66 (as of September 30, 2026)
- Sector / Industry: Biotechnology and Medical Research
